Scholar Rock Holding (SRRK) Research & Development (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Research & Development of $51.8 million for Q1 2026, up 6.44% year-over-year from $48.7 million in Q1 2025, and up 10.54% quarter-over-quarter from $46.9 million in Q4 2025.
Scholar Rock Holding (SRRK) Research & Development (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Research & Development history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- In Q1 2026, Research & Development rose 6.44% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $211.6 million (up 11.28% YoY), while the FY2025 annual figure was $208.4 million, up 12.95% from the prior year.
- Research & Development for Q1 2026 stood at $51.8 million, up from $46.9 million in the prior quarter.
- The five-year high for Research & Development was $62.4 million in Q2 2025, with the low at $26.9 million in Q2 2023.
- The 5-year median for Research & Development is $42.4 million (2024), against an average of $40.7 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development fell 16.23% in 2023, then soared 60.59% in 2024.
- Scholar Rock Holding's Research & Development stood at $29.6 million in 2022, then rose by 18.06% to $35.0 million in 2023, then surged by 44.06% to $50.4 million in 2024, then declined by 6.93% to $46.9 million in 2025, then advanced by 10.54% to $51.8 million in 2026.
- Business Quant data shows SRRK's Research & Development at $51.8 million in Q1 2026, $46.9 million in Q4 2025, and $50.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 58.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.23 Mn |
| Mar 31, 2026 | 51.81 Mn |
| Dec 31, 2025 | 46.88 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 62.40 Mn |
| Mar 31, 2025 | 48.68 Mn |
| Dec 31, 2024 | 50.37 Mn |
| Sep 30, 2024 | 48.72 Mn |
| Jun 30, 2024 | 42.37 Mn |
| Mar 31, 2024 | 43.09 Mn |
| Dec 31, 2023 | 34.96 Mn |
| Sep 30, 2023 | 30.34 Mn |
| Jun 30, 2023 | 26.87 Mn |
| Mar 31, 2023 | 29.74 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 33.39 Mn |
| Jun 30, 2022 | 32.07 Mn |
| Mar 31, 2022 | 29.37 Mn |
| Dec 31, 2021 | 29.05 Mn |
| Sep 30, 2021 | 31.27 Mn |